Generate Biomedicines, Inc. - 8-K Filing
Generate Biomedicines reports Q3 2026 revenue of $4.2 million and net loss of $87.7 million while announcing $30 million upfront from Zealand Pharma collaboration. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $GENB
Read the full article at SEC EDGAR
Part of the story Generate Biomedicines, Inc. - 10-Q Filing (2 articles)